MRSN

Mersana Therapeutics (MRSN)

About Mersana Therapeutics (MRSN)

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Details

Daily high

$1.98

Daily low

$1.87

Price at open

$1.89

52 Week High

$6.28

52 Week Low

$1.06

Market cap

241.7M

Dividend yield

0.00%

Volume

549,201

Avg. volume

1.1M

P/E ratio

-2.28

Mersana Therapeutics News